| Name | Title | Contact Details |
|---|
Deep Expertise, Broad Reach Versiti is a strategic affiliation of successful healthcare organizations whose vision is to improve the health of patients as the national leader in innovative transfusion solutions for healthcare systems. Everyone in our nation’s healthcare system is seeking new and better ways to provide high-quality patient care at an affordable cost. Organizations that offer vital resources must also look at new models of operating that will continually improve patient outcomes, increase the quality of service, and reduce the cost of healthcare. Working together, Versiti offers hospitals a more comprehensive range of services, including transfusion medicine, transplantation, stem cell and cellular therapies, hematology, oncology and genomics. We are passionate about improving the lives of our patients and hospital partners. We apply our deep expertise in blood-related service to solve the toughest challenges Our expertise and resources lead to new products, solutions and services to meet patient and hospital needs. We Believe: By bringing together the industry’s best and brightest, the depth and breadth of our expertise sets us apart Our relationships with donors, patients and hospital partners inspire everything we do We offer best-in-class products and services Our work sets new standards for quality, efficiency and care Our approach will reshape our industry and create new ways to help people and communities thrive
Diadexus is a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, providing healthcare providers with actionable information for managing patients. We pioneered the testing of Lp-PLA2 (lipoprotein-associated phospholipase A2), a marker of vascular-specific inflammation that provides new information, over and above traditional risk factors measured in a lipid panel, and has over a decade of peer-reviewed literature validating this biomarker`s utility. Our products are the only two FDA-cleared tests to measure Lp-PLA2: The PLAC® Test ELISA Kit first cleared by the FDA in 2003 and The PLAC® Test for Lp-PLA2 Activity cleared in December 2014. Our pipeline of advanced cardiac biomarkers includes biomarkers for heart failure, proADM, proET-1 and proANP. Each marker gives distinct, additive information for healthcare providers over currently available markers. Diadexus also provides services to pharmaceutical partners to address the need to incorporate biomarkers in clinical development. Our portfolio of advanced cardiac biomarkers is available to be paired with novel therapeutics in development for indications where cardiovascular risk information would provide valuable insights. This information can be used by pharmaceutical companies in targeting the appropriate patient population and understanding the potential long-term side effects for their therapeutics, potentially avoiding long-term follow up studies.
Southwest Diagnostic Imaging Center is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Devers Eye Institute is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Biomagnetic Resonance is a Madison Heights, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.